Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

(Source: Global Banking And Finance) The pivotal efficacy and safety data provided in the application result from the SUNBEAM„¢ and RADIANCE„¢ Part B phase 3, multicenter, randomized, …